Aniket Bankar, MD, discusses why rusfertide is considered a promising therapeutic approach for patients with polycythemia vera.

Hence, just like low haemoglobin levels (less than 13.2 g/dL for men and 11.6 g/dL for women) necessitate medical ...

Protagonist Therapeutics has 2 attractive late-stage pipeline assets, but commercialized sales will not begin until 2027.

Two posters at the CHEST 2024 annual meeting revealed that 18% of eligible patients hospitalized with acute exacerbations of ...

Investigators added more data to an analysis first published in 2020 and got the same result: ruxolitinib beats other ...

An expert explained the importance of education and involvement in care for patients with myeloproliferative neoplasms.

Read on to learn what doctors look for in a routine blood test and what’s considered a healthy PCV range for Male, Female and ...

Chelated iron is a supplemental form of iron that has been chemically altered to allow it to pass through the digestive system without breaking apart. When a compound is "chelated,” metallic ions are ...

Though INCY's performance in the year so far has been good, increasing competition for Jakafi is a concern. We advise ...

Image Source: Zacks Investment Research Incyte’s lead drug, Jakafi, is a JAK1/JAK2 inhibitor approved for the treatment of polycythemia vera (PV) in adults who have had an inadequate response to ...

Ropeginterferon alfa-2b (Ropeg) is approved for the treatment of adults with polycythemia vera (PV). This report aims to analyze the ethnic sensitivity of Ropeg for the treatment of PV, comparing the ...

A low-potassium diet entails choosing low-potassium foods like poultry, berries, and pasta while avoiding foods high in potassium like fish, red meat, and potatoes. Your healthcare provider will ...